HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Dianzani autoimmune lymphoproliferative disease — Clinical Guidelines

Overview

Dianzani autoimmune lymphoproliferative disease (DADA2) is an autosomal recessive disorder characterized by a wide range of clinical manifestations including vasculitis, hematologic issues, and features that can overlap with autoimmune lymphoproliferative syndrome (ALPS), such as lymphadenopathy and splenomegaly 1.

Diagnosis

Clinical Criteria: Presence of lymphadenopathy, splenomegaly, and autoimmune manifestations 1 4.

Laboratory Tests: Elevated double-negative T cells (TCRαβ+ CD4- CD8-) and functional defect in FAS-mediated apoptosis 4.

Genetic Testing: Identification of mutations in the ADA2 gene 1.

Differential Diagnosis: Distinguish from other lymphoproliferative disorders like EBV-associated T-cell LPD 2 and PTLD 8.

Management

First-Line Treatments: Corticosteroids and immunosuppressive agents (e.g., calcineurin inhibitors) for managing autoimmune manifestations 1 4.

Adjunctive Therapies: Rituximab may be considered for severe cases, though caution is advised due to potential HBV reactivation risks 3.

Bone Marrow Transplantation: Considered for severe refractory cases 5.

Special Populations

Pediatrics: Early onset can present with severe hematologic involvement requiring prompt intervention 5 6.

Comorbidities: Careful monitoring for infections like CMV in patients with defective apoptosis pathways 6.

Key Recommendations

Genetic Testing for ADA2 Mutations is essential for definitive diagnosis of DADA2 1. (Evidence: Strong)

Monitor for Double-Negative T Cells and FAS-Mediated Apoptosis Defects to support ALPS-like diagnosis 4. (Evidence: Moderate)

Consider Bone Marrow Transplantation in patients with severe, refractory autoimmune and hematologic manifestations 5. (Evidence: Weak)

References

1 Dell'Orso G, Grossi A, Penco F, Caorsi R, Palmisani E, Terranova P et al.. Case Report: Deficiency of Adenosine Deaminase 2 Presenting With Overlapping Features of Autoimmune Lymphoproliferative Syndrome and Bone Marrow Failure. Frontiers in immunology 2021. link 2 Chen G, Chen L, Qin X, Huang Z, Xie X, Li G et al.. Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome. International journal of clinical and experimental pathology 2014. link 3 Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM et al.. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of oncology : official journal of the European Society for Medical Oncology 2011. link 4 Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, Neven B, Schaffner C, Ducrot N et al.. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 2009. link 5 Kahwash SB, Fung B, Savelli S, Bleesing JJ, Qualman SJ. Autoimmune lymphoproliferative syndrome (ALPS): a case with congenital onset. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2007. link 6 Arkwright PD, Rieux-Laucat F, Le Deist F, Stevens RF, Angus B, Cant AJ. Cytomegalovirus infection in infants with autoimmune lymphoproliferative syndrome (ALPS). Clinical and experimental immunology 2000. link 7 Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatric clinics of North America 2000. link70272-8) 8 Hague K, Catalano P, Rothschild M, Strauchen J, Fyfe B. Posttransplant lymphoproliferative disease presenting as sudden respiratory arrest in a three-year-old child. The Annals of otology, rhinology, and laryngology 1997. link 9 Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N et al.. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet (London, England) 1996. link02293-3) 10 Solomon AR. Retroviruses and lymphoproliferative disease. Dermatologic clinics 1985. link 11 Liss L, Gogate SA. Diffuse reticulosis with leukomalacia. Acta neuropathologica. Supplementum 1975. link

Dianzani autoimmune lymphoproliferative disease